Follow @keithspeights
Recent articles
Is Novavax Stock a Buy?
The biotech's growth prospects still appear to clearly outweigh its risks.
What's Behind Guardant Health's Disappointing Q4 Results
The company beat revenue expectations, but its bottom-line performance and 2021 outlook weren't what investors hoped for.
Is GrowGeneration Stock a Buy?
Here are the arguments both for and against the high-flying stock.
Innovative Industrial Properties' Revenue and Earnings More Than Double in Q4
But the cannabis-focused REIT didn't meet Wall Street's expectations.
3 Growth Stocks You'll Want to Buy in the Next Market Crash
Any short-term pullback could present a great opportunity to buy these long-term winners.
Why Poseida Therapeutics Stock Is Popping Today
The biotech reported pipeline progress at its virtual R&D Day.
Why Owens & Minor Stock Is Skyrocketing Today
The company announced great Q4 results.
Why DermTech Stock Is a Buy Right Now
This high-flying healthcare stock should have more room to run.
1 Big Problem Ocugen Could Face That Investors Might Be Overlooking
This issue won't affect just Ocugen.
98 Million Reasons Sundial Growers Isn't a Great Stock to Buy Right Now
Actually, there are a few more than 98 million.
Is Fulgent Genetics Still a Good Stock to Buy?
It's a volatile stock right now. But the future for genomic testing looks bright.
Why Wall Street Wasn't Bothered by Jazz Pharmaceuticals' Mixed Q4 Results
The company beat top-line estimates, but missed on the bottom line.
Why Has Pfizer Stock Floundered?
There are two main reasons. At least one of them, though, isn't a problem anymore.
Should Investors Worry About Moderna's Vaccine Delays?
The short answer: No.
Should You Buy CVS Health Stock After Its Q4 Update?
The pharmacy retailer and health insurer topped Wall Street estimates but could face some challenges in 2021.
What Are Johnson & Johnson's Chances of Success With Its COVID Vaccine?
The clock is ticking until an FDA advisory committee reviews the healthcare giant's vaccine.
Warren Buffett Just Bought These 2 Dirt-Cheap Stocks. Should You?
Yes -- if you're looking for the same qualities in a stock that the billionaire investor is.
Why This Pet Stock Is a Better Bet Than Zomedica
It's not that Zomedica is necessarily a bad pick. The chances of long-term success, though, are higher with another stock.
2 Reasons Pfizer's COVID Vaccine Prospects Just Got Even Better
The good news keeps on coming.
Why Invitae Stock Fell 11.1% Today
There's nothing to be alarmed about.